Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Current Recommendations on Managing GI Adverse Reactions Associated …

Alberto Zambelli

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

Oncologists' Perspectives on the Effects of Time Toxicity in Cancer …

Safiya Karim

The ABCs of the CBC - Overview and Practical Insights on RBC Paramet…

The Blood Project

W. Aird

Recent Advances in Classical Hematology

Indy Hematology Review

R. Brodsky

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

Managing Dermatologic Toxicities: Cutaneous irAEs Associated with Im…

Cleveland Clinic Taussig Cancer Institute

R. Unwala

Putting the Freeze on Cold Agglutinin Disease

i3 Health

C. Broome

Clots in the Visceral and Cerebral Veins: Evidence, Guidelines and T…

Marc Zumberg

Infectious Complications of Checkpoint Inhibitors: Discussing Overla…

Cleveland Clinic Taussig Cancer Institute

Z. Yetmar

2024 Benign Hematology Updates

University of Colorado Division of Hematology

L. Chu

PKD: Diagnosis, Treatment and Monitoring for Complications

Stanford Medicine

M. Chien

Managing Women's Health in Menopause: Evolving Approaches for the Ma…

PleXus Communications

J. Simon, T. Iyer, A. Fiffick, M. Minkin

Mitapivat in PKD: Results of the ACTIVATE Trial and Updated Treatmen…

Stefan Eber